Literature DB >> 10477829

The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes.

A Bordoni1, P Biagi, S Hrelia.   

Abstract

The clinical use of the antitumoral doxorubicin (DOX) is limited by its cardiotoxicity, which is mediated through different mechanisms. The membrane lipid peroxidation induced by DOX may cause disruption of the unsaturated fatty acyl chains; in the endoplasmic reticulum, containing the system catalyzing the desaturation/elongation of fatty acids, DOX could interfere with the metabolism of linoleic and alpha-linolenic acids. Using primary cultures of neonatal rat cardiomyocytes we demonstrated that the exposure to different concentrations of DOX (10(-5) and 10(-7) M) for 24 h caused an increase in the production of conjugated dienes, an impairment in the desaturation/elongation of essential fatty acids, and a reduction in the cellular content of highly unsaturated fatty acids. Conversely, 1 h exposure to 10(-5) M DOX was sufficient to induce alterations in the desaturation/elongation of linoleic and alpha-linolenic acids, but did not cause either formation of conjugated dienes or modification of the fatty acyl pattern. Therefore, DOX has a dual negative effect, depending on its concentration and on the time of exposure, one directed against the membrane highly unsaturated fatty acids, the other against the system which is required for the synthesis of these fatty acids themselves. These two effects synergically act in causing heart cell damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477829     DOI: 10.1016/s1388-1981(99)00113-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte.

Authors:  Suresh N Kumar; Eugene A Konorev; Deepika Aggarwal; Balaraman Kalyanaraman
Journal:  J Proteomics       Date:  2011-02-19       Impact factor: 4.044

2.  Anthracycline-based combined chemotherapy in the mouse model.

Authors:  M Popovic; J Kolarovic; M Mikov; S Trivic; B Kaurinovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Apr-Jun       Impact factor: 2.441

3.  Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application.

Authors:  Guangguo Tan; Ziyang Lou; Wenting Liao; Zhenyu Zhu; Xin Dong; Wei Zhang; Wuhong Li; Yifeng Chai
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

4.  A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment.

Authors:  Yu Chen; Yong Tang; Ya-Chen Zhang; Xiao-Hong Huang; Yu-Quan Xie; Yin Xiang
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

5.  Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity.

Authors:  Rui Guo; Yinan Hua; Jun Ren; Karin E Bornfeldt; Sreejayan Nair
Journal:  Cell Death Dis       Date:  2018-06-07       Impact factor: 8.469

Review 6.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Authors:  Atiar M Rahman; Syed Wamique Yusuf; Michael S Ewer
Journal:  Int J Nanomedicine       Date:  2007

7.  Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer.

Authors:  Xiulan Chen; Shasha Wei; Ying Ma; Jie Lu; Gang Niu; Yanhong Xue; Xiaoyuan Chen; Fuquan Yang
Journal:  Theranostics       Date:  2014-09-18       Impact factor: 11.556

8.  Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment.

Authors:  Chen Xiong; Yan-Zhao Wu; Yu Zhang; Zi-Xiao Wu; Xue-Yan Chen; Ping Jiang; Hui-Cai Guo; Ke-Rang Xie; Ke-Xin Wang; Su-Wen Su
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.